You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bosutinib

Showing 26 - 50 of 72
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mild Cognitive Impairment, Dementia Trial in Santa Monica (bosutinib)

Enrolling by invitation
  • Mild Cognitive Impairment
  • Dementia
  • bosutinib
  • Santa Monica, California
    Neurological Associates of West LA
Feb 25, 2021

The Life After Stopping Tyrosine Kinase Inhibitors Study

Completed
  • Leukemia, Myeloid, Chronic
  • Imatinib (Stopping their TKI)
  • +3 more
  • San Francisco, California
  • +15 more
Jan 3, 2023

Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30

Terminated
Has Results
  • Blasts Under 15 Percent of Bone Marrow Nucleated Cells
  • +4 more
  • Bosutinib
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Apr 22, 2020

Leukemia, Myelogenous, Chronic Trial in Monza, Milano (Bosutinib, Bone Marrow Transplant, Bone Marrow cells)

Completed
  • Leukemia
  • +3 more
  • Bosutinib
  • +2 more
  • Monza, Italy/MB, Italy
  • +1 more
Nov 3, 2020

Chronic Myeloblastic Leukaemia Trial in Spain (Bosutinib)

Completed
  • Chronic Myeloblastic Leukaemia
  • Bosutinib
  • Gran Canaria, Spain
  • +12 more
Apr 28, 2020

Chronic Myeloid Leukemia (CML) Trial in Italy (Ponatinib 15mg QD, Ponatinib 30mg QD)

Not yet recruiting
  • Chronic Myeloid Leukemia (CML)
  • Ponatinib 15mg QD
  • Ponatinib 30mg QD
  • Cagliari, Italy
  • +12 more
Jan 31, 2021

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)

Recruiting
  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
  • Longmont, Colorado
  • +128 more
Aug 1, 2022

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Uijeongbu si (Asciminib single agent, Asciminib, Imatinib)

Recruiting
  • Chronic Myelogenous Leukemia
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Asciminib single agent
  • +5 more
  • Ann Arbor, Michigan
  • +49 more
Jan 26, 2023

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in United States (Bosutinib, Dasatinib, Laboratory Biomarker

Active, not recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Bosutinib
  • +5 more
  • Anchorage, Alaska
  • +540 more
Dec 14, 2022

Describe The Real World Use Of Bosutinib In The UK And

Completed
Has Results
  • Chronic Myeloid Leukaemia
  • Bosutinib
  • Liverpool, Merseyside, United Kingdom
  • +2 more
May 1, 2019

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive Trial in Worldwide

Completed
Has Results
  • Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
  • Anaheim, California
  • +188 more
Apr 16, 2021

TKI Discontinuation in CML Patients of China

Recruiting
  • Leukemia
  • +4 more
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Mar 15, 2022

    Needs of 3L+ CP-CML and With T315I-mutated CML Patients

    Completed
    • Chronic Myeloid Leukemia
    • 3L Therapy
    • T315I
    • Lyon, France
      Novartis Investigative Site
    Nov 9, 2022

    Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL

    Active, not recruiting
    • Chronic Phase Chronic Myeloid Leukemia
      • Chicago, Illinois
      • +24 more
      May 24, 2021

      Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in

      Completed
      Has Results
      • Recurrent Acute Leukemia of Ambiguous Lineage
      • +5 more
      • Chemosensitivity Assay
      • +4 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jun 29, 2022

      Cancer Target Therapy Efficacy

      Active, not recruiting
      • Cancer
      • RNA sequencing
      • +5 more
      • Walnut, California
      • +6 more
      Sep 13, 2021

      Leukemia, Myeloid, Chronic-Phase Trial in France (Pioglitazone, Avelumab)

      Recruiting
      • Leukemia, Myeloid, Chronic-Phase
      • Angers, France
      • +22 more
      Aug 6, 2020

      Real-World Usage of Asciminib Among Chronic Myeloid Leukemia in

      Completed
      • Chronic Myeloid Leukemia
        • East Hanover, New Jersey
          Novartis
        Nov 20, 2023

        Innate CD8+ T Cells and Evolution of Tyrosine Kinase Inhibitor

        Recruiting
        • Leukemia
        • +3 more
        • Phenotyping of total and innate CD8+T cells by flow cytometry
        • Nîmes, Gard, France
          CHU de Nîmes
        Jul 19, 2021

        Chronic Myeloid Leukemia Trial in Worldwide (Bosutinib, imatinib)

        Completed
        Has Results
        • Chronic Myeloid Leukemia
        • Anaheim, California
        • +165 more
        Dec 19, 2018

        Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in Moscow, St. Petersburg (PF-114)

        Unknown status
        • Chronic Myeloid Leukemia
        • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
        • Moscow, Russian Federation
        • +2 more
        Feb 13, 2020

        Chronic Myelogenous Leukaemia Trial in Bonn (Bosulif)

        Unknown status
        • Chronic Myelogenous Leukaemia
        • Bonn, Germany
          University Hospital Bonn
        Jun 28, 2017

        Chronic Myeloid Leukemia Trial in Worldwide (Bosutinib)

        Completed
        Has Results
        • Chronic Myeloid Leukemia
        • Bosutinib
        • Duarte, California
        • +110 more
        Jun 28, 2017

        Chronic Myeloid Leukemia Trial in Hong Kong

        Recruiting
        • Chronic Myeloid Leukemia
          • Hong Kong, Hong Kong
            The University of Hong Kong
          Aug 9, 2018

          Glioblastoma Trial in Boston (bosutinib)

          Completed
          Has Results
          • Glioblastoma
          • bosutinib
          • Boston, Massachusetts
          • +1 more
          Jun 23, 2016